Einsatz von PSMA-PET/CT beim Prostatakarzinom

In den letzten Jahren hat die PSMA-Liganden-PET vielversprechende Ergebnisse gezeigt und so enorm an Bedeutung bei der Versorgung von Prostatakarzinompatienten gewonnen. Dieser Beitrag soll einen Überblick zur PSMA-PET/CT in unterschiedlichen klinischen Situationen geben und auf aktuelle prospektive Studienergebnisse eingehen, welche den Stellenwert der PSMA-vermittelten Hybridbildgebung in den kommenden Jahren noch weiter steigern werden.

• Literatur

• 1 Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V.. Krebs in Deutschland 2015/2016 (12. Aufl). Berlin: Robert Koch-Institut; 2019: 98-101
• 2 Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF. Leitlinienprogramm Onkologie: Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 5.0. 2018. Im Internet (Stand: 14.09.2020): http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom
• 3 Barnes B, Kraywinkel K, Nowossadeck E. et al. Bericht zum Krebsgeschehen in Deutschland 2016. Berlin: Robert Koch-Institut; 2016
• 4 Torre LA, Siegel RL, Ward EM. et al. Global cancer incidence and mortality rates and trends – an update. Cancer epidemiology, biomarkers & prevention. The American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2016; 25: 16-27
• 5 Ferlay J, Ervik M, Lam F. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer; 2018. Im Internet (Stand: 14.09.2020): https://gco.iarc.fr/today
• 6 Hövels AM, Heesakkers RA, Adang EM. et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008; 63: 387-395
• 7 Evangelista L, Guttilla A, Zattoni F. et al. Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate-to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol 2013; 63: 1040-1048
• 8 Nanni C, Zanoni L, Pultrone C. et al. (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial. Eur J Nucl Med Mol Imaging 2016; 43: 1601-1610
• 9 Silver DA, Pellicer I, Fair WR. et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3: 81-85
• 10 Mannweiler S, Amersdorfer P, Trajanoski S. et al. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res 2009; 15: 167-172
• 11 Bostwick DG, Pacelli A, Blute M. et al. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998; 82: 2256-2261
• 12 Bander NH, Trabulsi EJ, Kostakoglu L. et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 2003; 170: 1717-1721
• 13 Ahn T, Roberts MJ, Abduljabar A. et al. A review of prostatespecific membrane antigen (PSMA) Positron emission tomography (PET) in renal cell carcinoma (RCC). Mol Imaging Biol 2019; 21: 799-807
• 14 Sasikumar A, Joy A, Nanabala R. et al. (68)Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2016; 43: 795-796
• 15 Shetty D, Loh H, Bui C. et al. Elevated 68Ga Prostate-Specific Membrane Antigen Activity in Metastatic Non-Small Cell Lung Cancer. Clin Nucl Med 2016; 41: 414-416
• 16 Kanthan GL, Coyle L, Kneebone A. et al. follicular lymphoma showing avid uptake on 68Ga PSMA-HBED-CC PET/CT. Clin Nucl Med 2016; 41: 500-501.000000001169
• 17 Haffner MC, Kronberger IE, Ross JS. et al. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol 2009; 40: 1754-1761
• 18 Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004; 91: 528-539
• 19 Budäus L, Leyh-Bannurah SR, Salomon G. et al. Initial experience of (68)Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol 2016; 69: 393-396
• 20 Eder M, Schafer M, Bauder-Wust U. et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjugate Chem 2012; 23: 688-697
• 21 Afshar-Oromieh A, Malcher A, Eder M. et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013; 40: 486-495
• 22 Maurer T, Eiber M, Schwaiger M. et al. Current use of PSMAPET in prostate cancer management. Nat Rev Urol 2016; 13: 226-235
• 23 Rowe SP, Gorin MA, Allaf ME. et al. PET imaging of prostatespecific membrane antigen in prostate cancer: current state of the art and future challenges. Prostate Cancer prostatic Dis 2016; 19: 223-230
• 24 Kesch C, Kratochwil C, Mier W. et al. (68)Ga or (18)F for prostate cancer imaging?. J Nucl Med 2017; 58: 687-688
• 25 Eiber M, Weirich G, Holzapfel K. et al. Simultaneous (68)Ga-PSMA HBED-CC PET/MRI Improves the localization of primary prostate cancer. Eur Urol 2016; 70: 829-836
• 26 Giesel FL, Sterzing F, Schlemmer HP. et al. Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer. Eur J Nucl Med Mol Imaging 2016; 43: 1400-1406
• 27 Herlemann A, Wenter V, Kretschmer A. et al. (68)Ga-PSMA positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer. Eur Urol 2016; 70: 553-557
• 28 Pyka T, Okamoto S, Dahlbender M. et al. Comparison of bone scintigraphy and (68)Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging 2016; 43: 2114-2121
• 29 Hofman MS, Lawrentschuk N, Francis RJ. et al. Prostatespecific membrane antigen PET-CT in patients with highrisk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020; 395: 1208-1216
• 30 Gorin MA, Rowe SP, Patel HD. et al. Prostate specific membrane antigen targeted (18)F-DCFPyL positron emission tomography/computerized tomography for the preoperative staging of high risk prostate cancer: results of a prospective, phase II, single center study. J Urol 2018; 199: 126-132
• 31 Kronke M, Wurzer A, Schwamborn K. et al. Histologicallyconfirmed diagnostic efficacy of (18)F-rhPSMA-7 positron emission tomography for N-staging of patients with primary high risk prostate cancer. J Nucl Med 2019;
• 32 Mottet N, Bellmunt J, Bolla M. et al. EAU-ESTRO-SIOG Guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol 2017; 71: 618-629
• 33 Cornford P, Bellmunt J, Bolla M. et al. EAU-ESTRO-SIOG Guidelines on prostate cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 2017; 71: 630-642
• 34 Vargas HA, Martin-Malburet AG, Takeda T. et al. Localizing sites of disease in patients with rising serum prostatespecific antigen up to 1 ng/ml following prostatectomy: How much information can conventional imaging provide?. Urol Oncol 2016; 34: 482.e5-482.e10
• 35 Afshar-Oromieh A, Avtzi E, Giesel FL. et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42: 197-209
• 36 Eiber M, Maurer T, Souvatzoglou M. et al. Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med 2015; 56: 668-674
• 37 Krause BJ, Souvatzoglou M, Tuncel M. et al. The detection rate of [11C]choline-PET/CT depends on the serum PSAvalue in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35: 18-23
• 38 van Leeuwen PJ, Stricker P, Hruby G. et al. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU international 2016; 117: 732-739
• 39 Morigi JJ, Stricker PD, van Leeuwen PJ. et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising psa after curative treatment and are being considered for targeted therapy. J Nucl Med 2015; 56: 1185-1190
• 40 Fendler WP, Calais J, Eiber M. et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol 2019;
• 41 Calais J, Ceci F, Eiber M. et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. The Lancet Oncology 2019; 20: 1286-1294
• 42 Giesel FL, Will L, Kesch C. et al. Biochemical recurrence of prostate cancer: initial results with [(18)F]PSMA-1007 PET/CT. J Nucl Med 2018; 59: 632-635
• 43 Afshar-Oromieh A, Holland-Letz T, Giesel FL. et al. Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging 2017; 44: 1258-1268
• 44 Fendler WP, Weber M, Iravani A. et al. Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res 2019; 25: 7448-7454
• 45 Dewes S, Schiller K, Sauter K. et al. Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study. Radiat Oncol 2016; 11: 73
• 46 Sterzing F, Kratochwil C, Fiedler H. et al. (68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. Eur J Nucl Med Mol Imaging 2016; 43: 34-41
• 47 von Eyben FE, Kiljunen T, Kangasmaki A. et al. Radiotherapy boost for the dominant intraprostatic cancer lesion-a systematic review and meta-analysis. Clinl Genitourin Cancer 2016; 14: 189-197
• 48 Rauscher I, Krönke M, König M. et al. Matched-pair comparison of (68)Ga-PSMA-11 PET/CT and (18)F-PSMA-1007 PET/CT: Frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy. J Nucl Med 2020; 61: 51-57